SFE Investment Counsel held its stake in shares of Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,436 shares of the biopharmaceutical company’s stock at the end of the second quarter. SFE Investment Counsel’s holdings in Pfizer were worth $297,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in PFE. Bloom Tree Partners LLC purchased a new stake in Pfizer during the first quarter worth approximately $35,682,000. BlackRock Group LTD increased its stake in Pfizer by 5.6% in the first quarter. BlackRock Group LTD now owns 59,474,971 shares of the biopharmaceutical company’s stock worth $1,762,838,000 after buying an additional 3,154,116 shares in the last quarter. Franklin Resources Inc. increased its stake in Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock worth $1,864,446,000 after buying an additional 9,005,107 shares in the last quarter. NN Investment Partners Holdings N.V. purchased a new stake in Pfizer during the first quarter worth approximately $242,144,000. Finally, BlackRock Fund Advisors increased its stake in Pfizer by 1.5% in the first quarter. BlackRock Fund Advisors now owns 92,489,121 shares of the biopharmaceutical company’s stock worth $2,741,378,000 after buying an additional 1,403,646 shares in the last quarter. 69.66% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Pfizer Inc. (NYSE:PFE) traded up 0.48% on Tuesday, reaching $33.81. The company’s stock had a trading volume of 14,113,245 shares. The company has a market cap of $205.08 billion, a P/E ratio of 29.97 and a beta of 0.87. Pfizer Inc. has a 52-week low of $28.25 and a 52-week high of $37.39. The company has a 50 day moving average price of $34.90 and a 200 day moving average price of $33.84.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. The company had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.56 EPS. On average, analysts anticipate that Pfizer Inc. will post $2.46 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, September 1st. Stockholders of record on Friday, August 5th were paid a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.55%. The ex-dividend date was Wednesday, August 3rd. Pfizer’s dividend payout ratio (DPR) is currently 95.24%.

PFE has been the topic of a number of research reports. Vetr raised Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 price objective on the stock in a research note on Monday, June 27th. Deutsche Bank AG reissued a “buy” rating and issued a $44.00 price objective on shares of Pfizer in a research note on Thursday, August 18th. Credit Suisse Group AG reissued an “outperform” rating and issued a $40.00 price objective on shares of Pfizer in a research note on Monday, August 22nd. Piper Jaffray Cos. set a $54.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, August 23rd. Finally, Jefferies Group set a $41.50 price objective on Pfizer and gave the stock a “buy” rating in a research note on Thursday, July 14th. Ten investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $38.78.

About Pfizer

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

5 Day Chart for NYSE:PFE

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.